Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2

被引:20
|
作者
Lu, Sheldon X. [1 ,4 ]
Fiorini, Tiago [1 ]
Lee, Jaebum [1 ]
Prasad, Hari S. [2 ]
Buxton, Amanda N. [3 ]
Bisch, Fredrick C. [4 ]
Dixon, Douglas R. [4 ]
Susin, Cristiano [1 ]
Wikesjoe, Ulf M. E. [1 ]
机构
[1] Georgia Regents Univ, LAPCR, Coll Dent Med, Augusta, GA 30912 USA
[2] Univ Minnesota, Hard Tissue Res Lab, Minneapolis, MN USA
[3] Medtron Spinal, Biol, Memphis, TN USA
[4] USA, Adv Educ Program Periodont, Ft Gordon, GA USA
关键词
biomaterials; bone; bone morphogenetic protein; osseointegration; tissue engineering; ALVEOLAR RIDGE AUGMENTATION; IMPLANT DEFECT MODEL; HISTOLOGIC OBSERVATIONS; CLINICAL-IMPLICATIONS; GRINDING TECHNIQUE; NONHUMAN-PRIMATES; TITANIUM IMPLANTS; BULKING AGENT; SPINE FUSION; BETA FAMILY;
D O I
10.1111/jcpe.12109
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Background Previous studies document the therapeutic potential of recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier for indications in the axial and appendicular skeleton. Nevertheless, the ACS does not comprise structural integrity to adequately support bone formation for onlay indications. The objective of this study was to evaluate local bone formation and osseointegration following surgical implantation of rhBMP-2 soak-loaded onto a compression resistant matrix (CRM). Methods Routine, contralateral, critical-size, supraalveolar, peri-implant defects in five adult male Hound Labrador mongrel dogs received 0.8mg rhBMP-2 soak-loaded onto either the ACS (benchmark control) or a CRM (collagen/-TCP/hydroxyapatite) followed by submerged wound closure for primary intention healing. The animals were euthanized at 8weeks for histologic/histometric evaluation. Results Healing was uneventful albeit considerable initial swelling was observed for either treatment. Sites receiving rhBMP-2/CRM showed significantly increased bone area (20.0 +/- 0.9 versus 12.3 +/- 2.6mm2, p=0.03) and bone density (24.1 +/- 1.4% versus 14.6 +/- 2.0%, p=0.04) compared with those receiving rhBMP-2/ACS. There were no significant differences between treatments for new bone height and osseointegration. Woven and lamellar trabecular bone lined with abundant osteoid was observed for all sites. Inconsistent cortex formation confirmed the immature nature of the newly formed bone. Seroma formation was observed for both treatments (80-100% of the animals/implants). Sites receiving rhBMP-2/CRM showed residual ceramic granules undergoing biodegradation, including accumulation of foamy macrophages. Conclusions rhBMP-2/CRM supports bone formation of clinically relevant geometry. Longer observation intervals as well as dose variations appear necessary to capture maturation of the newly formed bone, elimination of residual ceramic granules and resolution of seroma formation(s).
引用
收藏
页码:688 / 697
页数:10
相关论文
共 50 条
  • [1] Outcome of nonunion fractures in dogs treated with fixation, compression resistant matrix, and recombinant human bone morphogenetic protein-2
    Massie, Anna M.
    Kapatkin, Amy S.
    Fuller, Mark C.
    Verstraete, Frank J. M.
    Arzi, Boaz
    VETERINARY AND COMPARATIVE ORTHOPAEDICS AND TRAUMATOLOGY, 2017, 30 (02) : 153 - 159
  • [2] Clinical evaluation of recombinant human bone morphogenetic protein-2
    Valentin-Opran, A
    Wozney, J
    Csimma, C
    Lilly, L
    Riedel, GE
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2002, (395) : 110 - 120
  • [3] Recombinant human bone morphogenetic protein-2
    Shaffrey, Christopher I.
    Smith, Justin S.
    JOURNAL OF NEUROSURGERY-SPINE, 2013, 18 (02) : 109 - 110
  • [4] Recombinant human bone morphogenetic protein-2 Response
    Burkus, J. Kenneth
    JOURNAL OF NEUROSURGERY-SPINE, 2013, 18 (02) : 110 - 111
  • [5] Expression of bone morphogenetic protein in the course of osteoinduction by recombinant human bone morphogenetic protein-2
    Okubo, Y
    Bessho, K
    Fujimura, K
    Kusumoto, K
    Ogawa, Y
    Iizuka, T
    CLINICAL ORAL IMPLANTS RESEARCH, 2002, 13 (01) : 80 - 85
  • [6] Evaluation of the Healing Potential of Demineralized Dentin Matrix Fixed with Recombinant Human Bone Morphogenetic Protein-2 in Bone Grafts
    Kim, Sang-Yun
    Kim, Young-Kyun
    Park, Yeoung-Hyun
    Park, Joo-Cheol
    Ku, Jeong-Kui
    Um, In-Woong
    Kim, Ji-Yun
    MATERIALS, 2017, 10 (09):
  • [7] Long-Term Assessment of Bone Regeneration in Nonunion Fractures Treated with Compression-Resistant Matrix and Recombinant Human Bone Morphogenetic Protein-2 in Dogs
    Castilla, Andrea
    Filliquist, Barbro
    Spriet, Mathieu
    Garcia, Tanya C.
    Arzi, Boaz
    Chou, Po-Yen
    Kapatkin, Amy S.
    VETERINARY AND COMPARATIVE ORTHOPAEDICS AND TRAUMATOLOGY, 2023, 36 (01) : 29 - 38
  • [8] Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration
    Hollinger, JO
    Schmitt, JM
    Buck, DC
    Shannon, R
    Joh, SP
    Zegzula, HD
    Wozney, J
    JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1998, 43 (04): : 356 - 364
  • [9] Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
    Ghodadra, Neil
    Singh, Kern
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03): : 345 - 354
  • [10] BONE CELL INDUCTION BY RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2
    ALPASLAN, C
    IRIE, K
    OHASHI, N
    SAKAI, H
    KENMOTSU, S
    TAKAHASHI, K
    EJIRI, S
    NAKAJIMA, T
    OZAWA, H
    JOURNAL OF DENTAL RESEARCH, 1995, 74 (03) : 971 - 971